3 results
Part 1: The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to…
The primary objective of this study is to evaluate the effect of FES on participation level: achieving of individual goals, using the goal attainment scale (GAS)), and the Canadian Occupational Performance Measure (COPM) for the long term. Secondary…
To demonstrate the benefit of maintenance treatment with avelumab plus BSC vs. BSC alone in prolonging overall survival (OS) in patients with unresectable locally advanced or metastatic UC whose disease did not progress on or following completion of…